Inducible Mouse Models for Cancer Drug Target Validation.
10.15430/JCP.2016.21.4.243
- Author:
Joseph H JEONG
1
Author Information
1. Department of Developmental Biology and Genomics, College of Veterinary Medicine, Seoul National University and Korea Mouse Phenotyping Center, Seoul, Korea. jeongjoseph@snu.ac.kr
- Publication Type:Review
- Keywords:
Transgenic mouse;
Drug targeting;
Cancer;
Doxycycline
- MeSH:
Animals;
Biology;
Doxycycline;
Drug Delivery Systems;
Humans;
Mice*;
Mice, Transgenic;
Recurrence;
Transgenes;
United Nations
- From:Journal of Cancer Prevention
2016;21(4):243-248
- CountryRepublic of Korea
- Language:English
-
Abstract:
Genetically-engineered mouse (GEM) models have provided significant contributions to our understanding of cancer biology and developing anticancer therapeutic strategies. The development of GEM models that faithfully recapitulate histopathological and clinical features of human cancers is one of the most pressing needs to successfully conquer cancer. In particular, doxycycline-inducible transgenic mouse models allow us to regulate (induce or suppress) the expression of a specific gene of interest within a specific tissue in a temporal manner. Leveraging this mouse model system, we can determine whether the transgene expression is required for tumor maintenance, thereby validating the transgene product as a target for anticancer drug development (target validation study). In addition, there is always a risk of tumor recurrence with cancer therapy. By analyzing recurrent tumors derived from fully regressed tumors after turning off transgene expression in tumor-bearing mice, we can gain an insight into the molecular basis of how tumor cells escape from their dependence on the transgene (tumor recurrence study). Results from such studies will ultimately allow us to predict therapeutic responses in clinical settings and develop new therapeutic strategies against recurrent tumors. The aim of this review is to highlight the significance of doxycycline-inducible transgenic mouse models in studying target validation and tumor recurrence.
